Getting to BIDMC    Contact BIDMC    617-667-7000

Events Calendar    News    CAREERS @ BIDMC

ABOUT BIDMC CENTERS & DEPARTMENTS PATIENT & VISITOR INFORMATION YOUR HEALTH QUALITY & SAFETY MEDICAL EDUCATION RESEARCH GIVE TO BIDMC
 

BIDMC Research Investigator / Faculty Information

Michael B Atkins MD

Professor

Hematology and Oncology

Faculty Appointment:

Hematology and Oncology

   

Contact Information:

Michael B Atkins MD
Title:   Physician Professor
Office:   MB-412
Phone:   617-632-9250
Fax:   617-632-9260
Email:   matkins@bidmc.harvard.edu
Address:   Beth Israel Deaconess Medical Center
 330 Brookline Ave; MB-412
 Boston, MA 02215

Advanced Degree And Training Info:

Year

Institution

Area or Rank


No data available

Research Team Listing

Uma Akella MS

Kathleen Bear Christine Conley Arlene Hsu RN

Aline Nandelstadt MS

Andrew Percy BS

Areas of Interest:

Cancer & Hematologic

Genetics / Genomics GI / Renal / Epithelial Biology Immunology, Transplantation

Patient Oriented / Translational

   

Major Research Theme:

Biologic Therapy of melanoma and kidney cancer.
Mechanisms of response and resistance to therapy.
Kidney and Skin Cancer SPORE

Select Major Publications:    List of Publications via PubMed database at NIH NLM

Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L.  Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006; 12(7 Pt 2):2291s-2296s
Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG Jr, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the second Cambridge conference. Clin Cancer Res 2007;13(2):667s-70s
Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome of Interleukin-2 therapy for renal cancer. Clin Cancer Res 2005; 11(10):3714-21
Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou S-H, Marxhall B, Boni JP, Dukart G, Sheman ML. Randomized phase II study of multiple dose levels of CCI-779: A novel mTOR kinase inhibitor in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
Atkins MB, Gollob, J., Mier, J.W., McDermott, D.F., Tutin, L., Sorokin, P., Sosman, J.A. Phase II pilot trial of  concurrent biochemotherapy with cisplatin, vinblastine, temozolomide (CVT), interleukin-2 (IL-2) and interferonalpha-2B (IFN) in patients with metastatic melanoma.  Clin Cancer Res 2002; 8:3075-3081

External Recognition:

President Elect: Society For Biological Therapy
Medical Advisory Board Kidney Cancer Association
Scientific Advisory Board: Melanoma Research Foundation

Major Collaborative Activities:

Leader of the DF/HCC Kidney Cancer Program
Leader of the DF/HCC Kidney Cancer SPORE
Co-leader of the DF/HCC Skin Cancer SPORE
Deputy Chief, Division of Hematology/Oncology
Director of Biologic Therapy and Cutaneous Oncology Programs
Director, Cancer Clinical Trials Office
Associate Director for Clinical Research
Principal Investigator BIDMC ECOG Grant

Investigator's Web Site:

        

Harvard Catalyst Site:

   
 

Copyright 2009 Beth Israel Deaconess Medical Center | Contact Research Webmaster

IP Address: 38.107.191.87   |  Web Server: research.bidmc.harvard.edu   |  Database Server: Colorado\SQL17   |  App Path: /research/ResearchPIInfo.ASP   |  Version:

Browser: CCBot/1.0 (+http://www.commoncrawl.org/bot.html)
SecurityGroup: